EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis

Thota Ganesh iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00655 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Thota Ganesh. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia 30322, United States. Hauptthemen laut MEDLINE: Receptors, Prostaglandin E, Dinoprostone. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclooxygenase-1 and -2 (COX1 and COX2) derived endogenous ligand prostaglandin-E2 (PGE2) triggers several physiological and pathological conditions. It mediates signaling through four G-protein coupled receptors, EP1, EP2, EP3, and EP4. Among these, EP2 is expressed throughout the body including the brain and uterus. The functional role of EP2 has been extensively studied using EP2 gene knockout mice, cellular models, and selective small molecule agonists and antagonists for this receptor. The efficacy data from in vitro and in vivo animal models indicate that EP2 receptor is a major proinflammatory mediator with deleterious functions in a variety of diseases suggesting a path forward for EP2 inhibitors as the next generation of selective anti-inflammatory and antiproliferative agents. Interestingly in certain diseases, EP2 action is beneficial; therefore, EP2 agonists seem to be clinically useful. Here, we highlight the strengths, weaknesses, opportunities, and potential threats (SWOT analysis) for targeting EP2 receptor for therapeutic development for a variety of unmet clinical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Prostaglandin EDinoprostoneAnimalsMiceCyclooxygenase 2Drug DiscoveryReceptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 Subtype

Substanzen

Receptors, Prostaglandin EDinoprostoneCyclooxygenase 2Receptors, Prostaglandin E, EP2 SubtypeReceptors, Prostaglandin E, EP4 Subtype

Autor:innen und Institutionen

  • Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia 30322, United States.

ORCID-Profile: Thota Ganesh

Förderung

  • NINDS NIH HHS
  • NIA NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging

Zitieren

APA

Ganesh, T. (2023). Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00655

Vancouver

Ganesh T. Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00655

BibTeX
@article{Ganesh2023,
  author = {Ganesh, Thota},
  title = {Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00655}
}
Kostenlos starten →